This week on The Tox Lab, we’re discussing grey market peptides and examining the growing interest in these compounds for performance enhancement, recovery, and cosmetic purposes.
We begin by exploring peptides linked to musculoskeletal healing, focusing on BPC-157 and the evidence surrounding its proposed effects. We discuss the claims made about these compounds, the current state of the research, and the challenges of separating marketing from scientific evidence.
We then turn to melanotan II, examining its pharmacology, patterns of use, and a rare case of priapism associated with its administration.
Finally, we discuss the broader risks associated with grey market peptides, including product quality, dosing uncertainty, adverse effects, and the challenges posed by purchasing compounds from unregulated online sources.
Join us as we examine the evidence, harms, and controversies surrounding grey market peptides, and consider what their increasing popularity means for toxicology, public health, and consumer safety.
Hope you enjoy!
Links to the papers we discussed:
https://link.springer.com/article/10.1007/s12178-025-09990-7
https://academic.oup.com/smoa/article/9/1/100298/6956707
https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide
Disclaimer: All opinions are our own.
Find us on instagram: @the_tox_lab
Email us here: thetoxlab@gmail.com
Check out our new website: https://thetoxlab.co.uk/
Support us here: https://buymeacoffee.com/thetoxlab
